2023-12-01 08:00:00
Dupixent effective once morest BCPO
Sanofi released new data on its blockbuster drug Dupicent (dupilumab), evaluated in a second phase III trial once morest chronic obstructive pulmonary disease (COPD). These results confirm those of the first study, with a 34% reduction in disease exacerbations. As a result, filing a Supplemental Biologics License Application (sBLA) with the FDA is anticipated before the end of 2023.
A Valneva vaccine soon evaluated by the EMA
The EMA has agreed to examine the MA application of Valneva regarding its chikungunya vaccine. In the event of a favorable opinion, this active ingredient would be approved in Europe, and in the United States, where it has recently been authorized, under the nameIntoxicated. During its phase III, the compound demonstrated a seroresponse rate of 98.9%, 28 days following a single vaccination. The biotech is also awaiting clinical results for this vaccine in adolescent populations.
VOS INDICES
source
Phase III positive pour GSK
The British laboratory GSK announced positive phase III results for its Blenrep (belantamab mafodotin) for the treatment of relapsed or refractory multiple myeloma. In the study, the combination of Blenrep and BorDex (bortezomib, dexamethasone) significantly prolonged survival time without disease progression or delayed death, compared to standard of care daratumumab plus BorDex. The final results of the study are expected in the second half of 2024.
Selected for you
1701488449
#pipelines #Sanofi #Valneva #GSK